Two inactivated isolates of Borrelia burgdorferi initiate the production of borreliacidal antibodies against OspA and OspC to prevent Lyme infection. The only Lyme vaccine which is licensed to aid in the prevention of subclinical arthritis and other signs of Lyme disease. The vaccine contains a traditional isolate targeted at OspA and a unique isolate proven to induce high levels of Borreliacideal antibodies to OspC1.
Recommended for use in healthy dogs 8 weeks of age and older.
Package: 25 x 1 dose vials.